If you could vote on Brexit now which option would you choose?

Oxford Covid vaccine trial confirms encouraging results for the elderly

The coronavirus vaccine under development by Oxford university and AstraZeneca has elicited a strong immune response and been shown to be safe in older adults, a group at disproportionate risk of developing severe Covid-19. In phase 2 trial results published in The Lancet, researchers said the vaccine had fewer adverse effects in older people than in younger adults, and that it produced a similar immune response in both groups. The Financial Times first reported on the promising data last month. Testing of the Oxford-AstraZeneca vaccine is at an earlier stage than work on vaccines from Moderna and Pfizer-BioNTech, which trials suggest could protect about 95 per cent of people from infection.

Financial Times - November 19, 2020

View the full story here: https://www.ft.com/content/7ce02375-b66e-4e4d-a5d5-3084f1e83831